



Epogen, Procrit, Retacrit

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462
(800.88.CIGNA)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency: <input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication requested: <input type="checkbox"/> Epogen <input type="checkbox"/> Procrit <input type="checkbox"/> Retacrit <input type="checkbox"/> Other (please specify): Strength: Dosing schedule: J-Code: ICD10: Number of Injections per month: Expected duration: Patient's weight:					
Where will this medication be obtained? <input type="checkbox"/> Accredo Specialty Pharmacy** <input type="checkbox"/> Home Health / Home Infusion vendor <input type="checkbox"/> Hospital Outpatient <input type="checkbox"/> Physician's office stock (billing on a medical claim form) <input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Other (please specify): **Cigna's nationally preferred specialty pharmacy					
Facility and/or doctor dispensing and administering medication: Facility Name: State: Tax ID#: Address (City, State, Zip Code): Where will this drug be administered? <input type="checkbox"/> Patient's Home <input type="checkbox"/> Physician's Office <input type="checkbox"/> Hospital Outpatient <input type="checkbox"/> Other (please specify):					
NOTE: Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting. Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? <input type="checkbox"/> Yes <input type="checkbox"/> No (provide medical necessity rationale):					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No					
What is the patient's diagnosis? <input type="checkbox"/> Anemia in a Patient with Chronic Kidney Disease who is ON Dialysis <input type="checkbox"/> Anemia in a Patient with Chronic Kidney Disease who is NOT on Dialysis <input type="checkbox"/> Anemia in a Patient with Cancer due to Myelosuppressive Cancer Chemotherapy <input type="checkbox"/> Anemia Associated with Cancer in a Patient NOT Receiving Myelosuppressive Cancer Chemotherapy <input type="checkbox"/> Anemia Associated with Acute Myelogenous Leukemias (AML), Chronic Myelogenous Leukemias (CML), or other Myeloid Cancers <input type="checkbox"/> Anemia Associated with Radiotherapy in Cancer <input type="checkbox"/> Anemia Associated with Myelodysplastic Syndrome (MDS) <input type="checkbox"/> Anemia Associated with Myelofibrosis <input type="checkbox"/> Anemia in a Patient with Human Immunodeficiency Virus who is Receiving Zidovudine <input type="checkbox"/> Reduction of Allogeneic Red Blood Cell Transfusions in a Patient Undergoing Surgery <input type="checkbox"/> To Enhance Athletic Performance <input type="checkbox"/> Anemia due to Acute Blood Loss <input type="checkbox"/> Non-Anemic Patient (Hemoglobin greater than 13.0 g/dL) Prior to Surgery <input type="checkbox"/> Other					

(if other) Please provide the patient's diagnosis or reason for treatment.

Clinical Information:

(if CKD NOT on Dialysis) Is this initial therapy or is the patient currently receiving an Erythropoiesis-Stimulating Agent? Note: Examples of erythropoiesis-stimulating agents include an epoetin alfa product (for example, Epogen, Procrit, or Retacrit), a darbepoetin alfa product (for example, Aranesp), or a methoxy polyethylene glycol-epoetin beta product (for example, Mircera).

- Initial therapy
 Currently receiving an Erythropoiesis-Stimulating Agent

(if Myelosuppressive Chemo, MDS, Myelofibrosis, zidovudine HIV) Is this initial therapy or is the patient currently receiving an Erythropoiesis-Stimulating Agent? Note: Examples of erythropoiesis-stimulating agents include an epoetin alfa product (for example, Epogen, Procrit, or Retacrit) or a darbepoetin alfa product (for example, Aranesp).

- Initial therapy
 Currently receiving an Erythropoiesis-Stimulating Agent

(if CURRENTLY receiving CKD NOT on Dialysis, Myelosuppressive Chemo, MDS, Myelofibrosis, Zidovudine HIV) Does the patient have a hemoglobin less than or equal to 12.0 g/dL? Yes No

(if CKD NOT on Dialysis, Myelosuppressive Chemo, MDS, Myelofibrosis, Zidovudine HIV, Transfusions) Is the patient currently receiving iron therapy? Yes No

(if no) Does the patient have adequate iron stores according to the prescriber? Yes No

(if INITIAL, CKD NOT on Dialysis, 17 yr or younger) Does the patient have a hemoglobin less than or equal to 11.0 g/dL? Yes No

(if INITIAL, CKD NOT on Dialysis, 18 yr or older) Does the patient have a hemoglobin less than 10.0 g/dL? Yes No

(if Myelosuppressive Chemo) Is the patient currently receiving myelosuppressive chemotherapy? Yes No

(if yes) According to the prescriber, is the myelosuppressive chemotherapy considered non-curative? Yes No

(if INITIAL, Myelosuppressive Chemo) Does the patient have a hemoglobin less than 10.0 g/dL? Yes No

(if INITIAL, MDS/Myelofibrosis/Zidovudine HIV) Does the patient have a hemoglobin less than 10.0 g/dL? Yes No

(if no) Does the patient have a serum erythropoietin level less than or equal to 500 mU/mL? Yes No

(if MDS, Myelofibrosis) Is the requested medication being prescribed by (or in consultation with) a hematologist or oncologist? Yes No

(if Myelofibrosis, currently receiving) According to the prescriber, has the patient responded to therapy which is defined as a hemoglobin of greater than or equal to 10 g/dL? Yes No

(if no) According to the prescriber, has the patient's current hemoglobin increased by at least 2 g/dL since starting treatment? Yes No

(if Zidovudine HIV) Is the patient currently receiving zidovudine therapy? Yes No

(if Transfusions) Does the patient have a hemoglobin less than or equal to 13.0 g/dL? Yes No

(if Transfusions) Is your patient scheduled for elective surgery? Yes No

(if yes) Is your patient scheduled for vascular or cardiac surgery? Yes No

(if Transfusions) Is the patient NOT willing or able to donate autologous blood prior to surgery? Yes No

(if requesting Epogen) Has the patient tried Procrit [may require prior authorization]? Yes No

(If Yes) Is the patient unable to continue using Procrit due to a formulation difference in the inactive ingredient(s) [for example, differences in stabilizing agent, buffering agent, and/or surfactant] which, according to the prescriber, would result in a significant allergy or serious adverse reaction? Yes No

Additional Pertinent Information:

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermy meds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v031326

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005